YAP1 and pulmonary hypertension: Aberrant activation of YAP/TAZ contributes to a variety of cardiovascular conditions: atherosclerosis, pulmonary hypertension, myocardial hypertrophy, angiogenesis, restenosis, and myocardial fibrosis, while hypoactivation of YAP/TAZ is associated with aortic aneurysms, aortic dissection, reperfusion of myocardial ischemia, and myocardial infarction.